Tiziana Life Sciences Ltd Stock price

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Delayed Nasdaq 11:11:14 2024-03-28 am EDT 5-day change 1st Jan Change
0.4275 USD +2.52% Intraday chart for Tiziana Life Sciences Ltd -7.87% -23.66%
Sales 2021 - Sales 2022 - Capitalization 60.66M
Net income 2021 -23M Net income 2022 -15M EV / Sales 2021 -
Net cash position 2021 42.19M Net cash position 2022 17.76M EV / Sales 2022 -
P/E ratio 2021
-4.01 x
P/E ratio 2022
-3.95 x
Employees 9
Yield 2021 *
-
Yield 2022
-
Free-Float 29.71%
More Fundamentals * Assessed data
Dynamic Chart
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity MT
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis CI
Transcript : Tiziana Life Sciences Ltd - Shareholder/Analyst Call
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program MT
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis CI
Tiziana Life Sciences Says FDA Allows At-Home Use of Multiple Sclerosis Treatment; Shares Rise MT
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment CI
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab CI
Tiziana Life Sciences Says Multiple Sclerosis Drug Reduced Key Biomarker Based on PET Scan Results MT
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS) CI
Tiziana Life Sciences Initiates Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis MT
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis CI
More news

Latest transcript on Tiziana Life Sciences Ltd

1 day+10.22%
1 week-0.95%
Current month-4.37%
1 month-7.19%
3 months-19.21%
6 months-31.48%
Current year-17.93%
More quotes
1 week
0.41
Extreme 0.412
0.49
1 month
0.41
Extreme 0.412
0.54
Current year
0.41
Extreme 0.412
0.63
1 year
0.41
Extreme 0.412
1.39
3 years
0.41
Extreme 0.412
1.70
5 years
0.41
Extreme 0.412
1.70
10 years
0.41
Extreme 0.412
1.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 98-02-10
Director of Finance/CFO 47 -
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 76 20-06-30
Director/Board Member 72 15-10-31
Chief Executive Officer 52 98-02-10
More insiders
Date Price Change Volume
24-03-28 0.4275 +2.52% 17 917
24-03-27 0.417 -2.11% 64,900
24-03-26 0.426 -5.96% 73,939
24-03-25 0.453 -2.58% 79,854
24-03-22 0.465 +0.22% 19,443

Delayed Quote Nasdaq, March 28, 2024 at 09:41 am EDT

More quotes
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3303 GBP
Average target price
2.406 GBP
Spread / Average Target
+628.50%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Tiziana Life Sciences Ltd - Nasdaq